Clinical trials: Hyperlipoproteinemia (a)
Acute Coronary Syndrome
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission.
- Trial name
- ACS (NCT07102628)
- Testing
- Inclisiran
- Where
- 69 sites in Argentina, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Hyperlipidemia
A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single-dose of JS401 in healthy volunteers with normal or mildly elevated triglycerides.
- Trial name
- NCT06041165
- Testing
- JS401
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein…
- Trial name
- ORION-19 (NCT06597006)
- Testing
- Inclisiran
- Where
- 19 sites in United States, Austria and 9 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Left Ventricular Diastolic Dysfunction, Hyperlipidemias
Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia
preserved left ventricular ejection fraction (LVEF ≥ 50%) and are accompanied by dyslipidemia (LDL ≥ 100 mg / dl) will be enrolled. Only patients who do not meet the exclusion criteria should be enrolled in the study.
- Trial name
- NCT04433533
- Testing
- Rosuvastatin 20, Rosuvamibe 10/10
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Hyperlipidemia, Cardiovascular Diseases
Effects of a Long Term Dietary Portfolio and of Sequential Removal of Food Components From the Diet
The purpose of this study is to evaluate the long term effectiveness of the dietary portfolio, consisting of viscous fibers, soy products, nuts and plant sterols, as well as the effects of removing single food components from the…
- Conditions
- Hyperlipidemia, Cardiovascular Diseases, Hypercholesterolemia
- Trial name
- NCT00438893
- Testing
- Dietary portfolio of cholesterol-lowering foods
- Where
- Canada
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Hypercholesterolemia
Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH
The purpose is to study Safety and Tolerability.
- Trial name
- NCT01350960
- Testing
- SPC5001, Saline 0.9%
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Santaris Pharma A/S
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
The purpose of this study is to evaluate the efficacy and safety of SYH2053 monotherapy in patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia . This trial plans to enroll 760 Participants.
- Trial name
- NCT07421297
- Testing
- SYH2053 injection
- Where
- 2 sites in China
- Volunteers
- 760 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Dyslipidemias, Hyperlipidemias
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered…
- Conditions
- Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
- Trial name
- NCT04516291
- Testing
- Vupanorsen
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Pfizer
Oxidative Stress
Antioxidative Effect of Plantago Asiatica L. Extract
The purpose of this study is to evaluate the antioxidant effect of Plantago asiatica L. extract in subjects with mild hyperlipidemia.
- Trial name
- NCT01278589
- Testing
- Plantago asiatica L. extract 5g, Plantago asiatica L. extract 10g, Plantago asiatica L. extract 20g
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ewha Womans University
Hypercholesterolemia and Hyperlipidemia
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
In order to meet the preferences and needs of different patients for injection sites and improve the medication compliance of patients, it is planned to compare the bioavailability, pharmacokinetics, pharmacodynamic and safety…
- Trial name
- NCT05370950
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Familial Hypercholesterolemia
A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population
To determine the prevalence and the prognosis in a corhort of patients with familial hypercholesterolemia (FH).
- Trial name
- NCT04958629
- Testing
- familial hypercholesterolemia
- Volunteers
- 318 people
- Sponsor
- Peking University Third Hospital
Dyslipidemias, High Cholesterol
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- BROOKLYN (NCT05425745)
- Testing
- Obicetrapib
- Where
- 96 sites in United States, Canada and 8 more
- Volunteers
- 354 people
- Sponsor
- NewAmsterdam Pharma
Combined Hyperlipidemia
A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia
This is a multi-center, double blind, prospective, longitudinal, randomized, 12-week study with a 52-week open-label follow-up to evaluate the safety and efficacy of daily administration of Pravastatin 40 mg or Fenofibrate 160 mg…
- Trial name
- NCT00459745
- Testing
- Pravafen, Pravastatin, Fenofibrate
- Where
- 57 sites in United States
- Volunteers
- 481 people
- Sponsor
- Shionogi
Hyperlipidemia
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism
This study will evaluate the effects of encapsulated botanical extracts, previously shown to inhibit the enzyme diacylglycerol-acyltransferase-1 (DGAT-1) in vitro, on fasting and postprandial lipid metabolism during an oral fat…
- Trial name
- NCT02366156
- Testing
- Low Dose Grape Blend, High Dose Grape Blend
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Access Business Group
Hyperlipidemia
Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal
This study is designed to survey the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists; To survey the control rate of the patients with dyslipidemia in "real world"; and to evaluate the…
- Trial name
- CRE NIS (NCT00781560)
- Where
- 15 sites in China
- Volunteers
- 2,575 people
- Sponsor
- AstraZeneca
Healthy
A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects
The study is designed to determine the safety and tolerability of RN316 when administered intravenously to healthy adult subjects. This is the first time RN316 has been given to humans.
- Trial name
- NCT00991159
- Testing
- RN316
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertension, Hyperlipidemia
Cardiovascular Lifestyle Study: Effects and Expense of a Cardiovascular Risk Reduction Clinic in Primary Care
The purpose of this trial is to study the effects on risk reduction and expense of 3 approaches to the care of people with cardiovascular risk factors in a naturalistic primary care environment.
- Conditions
- Hypertension, Hyperlipidemia, Hyperglycemia, Cardiovascular Disease
- Trial name
- NCT00291824
- Testing
- Cardiovascular risk factors and willingness to change
- Where
- Canada
- Volunteers
- 670 people
- Sponsor
- Caroline Medical Group
Hypercholesterolemia, Familial
Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Homozygous Familial Hypercholesterolemia
- Trial name
- NCT00280995
- Testing
- ISIS 301012
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 12 people
- Sponsor
- Kastle Therapeutics, LLC
Hyperlipidemia
A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)
Great controversy exists about the feasibility and safety of a product that can be employed for self-directed cholesterol reduction.
- Trial name
- NCT01152073
- Testing
- Second Formulation, Third Formulation
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Healthy Drink Discoveries, Inc.
Hypertension, Hyperlipidemia
Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
A phase 3 study to evaluate efficacy and safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients with Hypertension and Dyslipidemia
- Trial name
- NCT02899455
- Testing
- HGP0904, HGP0608, HGP0816
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Hanmi Pharmaceutical Company Limited